Real Time Touch

new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)

Real Time Touch

Medimmune Limited patents

Recent patent applications related to Medimmune Limited. Medimmune Limited is listed as an Agent/Assignee. Note: Medimmune Limited may have other listings under different names/spellings. We're not affiliated with Medimmune Limited, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "M" | Medimmune Limited-related inventors

Antibodies to alpha-synuclein and uses thereof

The invention provides antibodies that specifically bind human α-synuclein with a high affinity and reduces α-synuclein spreading in vivo, recombinant polypeptides comprising said antibodies or antigen-binding fragment thereof and methods for generating such polypeptides, as well as compositions and methods for generating α-synuclein antibodies, and methods of using α-synuclein antibodies... Medimmune Limited

Pyrrolobenzodiazepines and conjugates thereof

A conjugate of formula (A): Wherein Y is selected from formulae A1 and A2: Z1 is a C1-3 alkylene group; Z2 is a C1-3 alkylene group; Q is: where QX is such that Q is an amino-acid residue, a dipeptide residue or a tripeptide residue; L is a linker connected... Medimmune Limited

Glucagon/glp-1 agonists for the treatment of obesity

This disclosure provides GLP-1/glue agon agonist peptides for the treatment of metabolic diseases, e.g., obesity.... Medimmune Limited

Therapeutic combinations and methods for treating neoplasia

The disclosure features a CXCR2 antagonist in combination with a checkpoint inhibitor (e.g., an anti-CTLA-4 antibody or an anti-PD-L1 antibody) and methods of using the combination to enhance anti-tumor activity in a subject.... Medimmune Limited

Binding proteins specific for lox1 and uses thereof

This disclosure provides LOX1 (LOX1) binding proteins such as anti-LOX1 antibodies, and compositions and methods for making these binding proteins. In certain aspects the LOX1-binding proteins provided herein, inhibit, or antagonize LOX1 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating conditions associated with atherosclerosis, thrombosis,... Medimmune Limited

Amino acid derivatives

There are provided amino acid derivatives of formula V and VI as defined herein which are pyrrolysine analogs for use in bioconjugation processes.... Medimmune Limited

Cell lines

There is provided inter alia a process for stabilizing a eukaryotic cell line which expresses PylRS and tRNAPyl and which is suitable for incorporation of a gene encoding a target protein containing one or more non-natural amino acids encoded by a nonsense codon which comprises culturing said cell line under... Medimmune Limited

Pyrrolobenzodiazepines and targeted conjugates

This invention relates to pyrrolobenzodiazepines (PBDs), in particular pyrrolobenzodiazepine dimers having a C2-C3 double bond and an aryl group at the C2 position in each monomer unit, and their inclusion in targeted conjugates. The differing substituent groups may offer advantages in the preparation and use of the compounds, particularly in... Medimmune Limited

Anti-cd22 antibodies and immunoconjugates

The invention provides anti-CD22 antibodies and immunoconjugates and methods of using the same.... Medimmune Limited

Pyrrolobenzodiazepines and targeted conjugates

(c) R10 is H and R11 is SOzM, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation, or both M together are a divalent pharmaceutically acceptable cation.... Medimmune Limited

Stable anti-il-4ra formulation

The present invention relates to a stable, low viscosity antibody formulation, wherein the formulation comprises a high concentration of anti-IL4R antibody. In some embodiments, the invention relates in general to a stable antibody formulation comprising about 100 mg/mL to about 200 mg/mL of an antibody or fragment thereof that specifically... Medimmune Limited

Methods for identifying patients responsive to anti-pd-l1 antibody therapy

The disclosure provides methods for treating lung cancer (e.g., non-small cell lung cancer) with an anti-PD-L1 antibody in a patient identified using a polynucleotide or polypeptide marker of the disclosure: CXCL9, KRT8, TRIM29, and/or IFNgamma.... Medimmune Limited

Humanized anti-tn-muc1 antibodies and their conjugates

Humanized anti-Tn-MUC1 antibodies and conjugates thereof. Conjugates comprising pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker to the antibody are described.... Medimmune Limited

Pyrrolobenzodiazepine-antibody conjugates

The present disclosure relates to the use of antibody-drug conjugates (ADCs) comprising pyrrolobenzodiazepine (PBD) dimers and anti-CD25 antibodies for use in treating disorders characterized by the presence of CD25+ve cells.... Medimmune Limited

Treatment for rheumatoid arthritis

Treatment of rheumatoid arthritis (RA) to provide clinical benefit in patients, including decrease in DAS28-CRP by more than 1.2 and/or improvement determined by ACR20, ACR50 or ACR70, comprising administering therapeutic antibody mavrilimumab.... Medimmune Limited

Pyrrolobenzodiazepines and conjugates thereof

A conjugate comprising a PBD dimer linked from the tether joining the two PBD units, wherein the linker is of formula (A1): (Formula (A1)) wherein RN1 is selected from H and C1-4 alkyl; L is a linker connected to a cell binding agent; CBA is the cell binding agent; n... Medimmune Limited

Intracellular antigen binding

The disclosure generally provides a Designed Ankyrin Repeat Protein (DARPin) that specifically binds to an antigen, the DARPin having an N-terminal cap section, at least two Ankyrin Repeat (AR) module sections, and a C-terminal cap section, characterized in that the DARPin has a charge that is less negative than known... Medimmune Limited

Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereof

This disclosure relates to combination therapies comprising anti-Pseudomonas Psl and PcrV bispecific binding molecules and related compositions, for use in prevention and treatment of Pseudomonas infection.... Medimmune Limited

Stabilized angiopoietin-2 antibodies and uses thereof

Stabilized antibodies directed to Angiopoeitin-2 and uses of such antibodies are described. Nucleic acid and amino acid sequences, hybridomas or other cell lines for expressing such antibodies are also provided.... Medimmune Limited

Ion channel modulators and uses thereof

The invention provides antibodies that specifically bind a P2X4 polypeptide and modulate P2X4 channel activity, recombinant P2X4 polypeptides and methods for generating such polypeptides, as well as compositions and methods for generating anti-P2X4 antibodies, and methods of using P2X4 antibodies for the treatment of neuropathic pain and other indications.... Medimmune Limited

Targeted pyrrolobenzodiazapine conjugates

Provided are Conjugate comprising PBDs conjugated to a targeting agent and methods of using such PBDs.... Medimmune Limited

Targeted binding agents against b7-h1

Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.... Medimmune Limited

Multispecific and multivalent binding proteins and uses thereof

The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making and using... Medimmune Limited

Human anti il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases

The present invention provides human anti-IL-6 antibodies with extended in vivo half-life. The invention further relates to pharmaceutical compositions, therapeutic compositions, and methods using therapeutic antibodies that bind to IL-6 and that has an extended in vivo half-life for the treatment and prevention of IL-6 mediated diseases and disorders, such... Medimmune Limited

Gitrl fusion proteins and uses thereof

The disclosure provides GITRL fusion polypeptide subunits comprising an IgG Fc domain, a trimerization domain, and the receptor binding domain of GITR ligand, where the fusion polypeptide subunits can self-assemble into hexameric proteins. Also provided are methods of making fusion polypeptide subunits and hexameric proteins, and methods of use, e.g.,... Medimmune Limited

Methods for treating hepcidin-mediated disorders

Methods for treating hepcidin-mediated disorders are provided.... Medimmune Limited

Anti-siglec-15 antibodies and uses thereof

This disclosure relates to anti-Siglec-15 antibodies and uses thereof, in particular in the treatment of leukaemia, such as acute myeloid leukaemia.... Medimmune Limited

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009


This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. is not affiliated or associated with Medimmune Limited in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Medimmune Limited with additional patents listed. Browse our Agent directory for other possible listings. Page by